CSTL (Castle Biosciences) Other Long Term Assets: $6.1 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CSTL Castle Biosciences Inc CSTL
82 GF Score
Price $31.29
GF Value $29.72
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Castle Biosciences Other Long Term Assets?

Castle Biosciences CSTL -3.04% 82 Other Long Term Assets is $6.1 Mil as of Jun. 2026. GuruFocus rates CSTL with a GF Score™ of 82/100 and a GF Value™ of $29.72 (Fairly Valued). The stock has 4 warning signs investors should review.

Castle Biosciences's other long-term assets for the quarter that ended in Jun. 2026 was $6.1 Mil.

Castle Biosciences's quarterly other long-term assets increased from Dec. 2025 ($5.6 Mil) to Mar. 2026 ($6.2 Mil) but then stayed the same from Mar. 2026 ($6.2 Mil) to Jun. 2026 ($6.1 Mil).

Castle Biosciences's annual other long-term assets declined from Dec. 2023 ($2.6 Mil) to Dec. 2024 ($2.1 Mil) but then increased from Dec. 2024 ($2.1 Mil) to Dec. 2025 ($5.6 Mil).

Castle Biosciences Other Long Term Assets Historical Data

* Premium members only.

The historical data trend for Castle Biosciences's Other Long Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Castle Biosciences Other Long Term Assets Chart

Castle Biosciences Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Long Term Assets
Get a 7-Day Free Trial Premium Member Only 3.02 2.20 2.63 2.15 5.65

Castle Biosciences Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Long Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.37 3.33 5.65 6.20 6.10
CSTL
82GF Score
Castle Biosciences Inc CSTL
Other Long Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Castle Biosciences Other Long Term Assets Calculation

GuruFocus lists Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets under the "Total Long-Term Assets" section.

Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.

Frequently Asked Questions Learn more about Other Long Term Assets →
What does a Other Long Term Assets of $6.1 Mil mean?
Castle Biosciences (CSTL) has a Other Long Term Assets of $6.1 Mil as of Jun. 2026. Other long-term assets as record on a company's balance sheet not categorized as standard assets. View historical data on Castle Biosciences and its competitors.
Is Castle Biosciences' Other Long Term Assets too high?
Castle Biosciences' current Other Long Term Assets is $6.1 Mil. Overall, Castle Biosciences has a GF Score™ of 82/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Castle Biosciences' Other Long Term Assets compare to OPK and FLGT?
Castle Biosciences' Other Long Term Assets of $6.1 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long Term Assets for a Medical Diagnostics & Research company?
A good Other Long Term Assets depends on the Medical Diagnostics & Research industry context. However, Other Long Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long Term Assets mean?
A high Other Long Term Assets can signal that a stock is expensive relative to its fundamentals. Other long-term assets as record on a company's balance sheet not categorized as standard assets. View historical data on Castle Biosciences and its competitors. Castle Biosciences's current Other Long Term Assets is $6.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Castle Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Castle Biosciences (CSTL) is currently considered Fairly Valued. The stock's GF Value™ is $29.72, compared to a current price of $31.29 — trading 5.3% above its estimated fair value. The current Other Long Term Assets is $6.1 Mil. Castle Biosciences' overall GF Score™ is 82/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long Term Assets calculated?
Other Long Term Assets is calculated from a company's financial statements. For Castle Biosciences (CSTL), the current Other Long Term Assets is $6.1 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Castle Biosciences (CSTL) Overvalued in 2026?

Based on GuruFocus' analysis, Castle Biosciences stock appears to be overvalued. The current stock price of $31.29 is trading 5.3% above its estimated GF Value™ of $29.72. GuruFocus considers Castle Biosciences to be Fairly Valued.

Key valuation signals for CSTL:

  • Other Long Term Assets: $6.1 Mil
  • GF Value™: $29.72 vs. price of $31.29 (5.3% above fair value)
  • GF Score™: 82/100 with 4 warning signs

No single metric tells the full story. See the CSTL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Castle Biosciences Business Description

Other Exchanges 086:Germany
Address 1500 West Parkwood Avenue, Suite 401, Friendswood, TX, USA, 77546
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.
82GF Score

Get the complete analysis for CSTL

Other Long Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$31.29
Price
$29.72
GF Value